Theseus Pharmaceuticals, Inc. THRX
4.07 +4.07
Day range unavailable
52-week range unavailable
Financial health
Altman Z-Score
10.00 Safe zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
3 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
Valuation
P/E -4.1×
FY 2019 5y median -28.1× FY 2022
P/S 0.0×
FY 2019 5y median 0.0× FY 2022
P/B 0.9×
FY 2019 5y median -6.4× FY 2022
P/FCF -5.7×
FY 2019 5y median -56.9× FY 2022
EV/EBITDA -1.9×
FY 2019 5y median -37.7× FY 2022
EV/Sales 0.0×
FY 2019 5y median 0.0× FY 2022
FCF Yield -17.4%
FY 2019 5y median -3.5% FY 2022
Profitability
Gross Margin 0.0%
FY 2019 5y median 0.0% FY 2022
Operating Margin 0.0%
FY 2019 5y median 0.0% FY 2022
Net Margin 0.0%
FY 2019 5y median 0.0% FY 2022
ROE -22.7%
FY 2019 5y median 12.0% FY 2022
ROIC -23.7%
FY 2019 5y median -60.6% FY 2022
ROA -21.2%
FY 2019 5y median -80.2% FY 2022
Growth (YoY)
Revenue 0.0%
FY 2019 FY 2022
Operating Income -97.9%
FY 2019 FY 2022
EPS (diluted) -60.5%
FY 2019 FY 2022
Free Cash Flow -22.9%
FY 2019 FY 2022
Financial Health
Current Ratio 17.8×
FY 2019 5y median 11.6× FY 2022
Quick Ratio 17.8×
FY 2019 5y median 11.6× FY 2022
Debt / Equity 0.0×
FY 2019 5y median 0.0× FY 2022
Net Debt / EBITDA 1.7×
FY 2019 5y median 1.5× FY 2022
Interest Coverage 0.0×
FY 2019 5y median 0.0× FY 2022
Dividends
Dividend Yield 0.0%
FY 2019 5y median 0.0% FY 2022
Payout Ratio 0.0%
FY 2019 5y median 0.0% FY 2022
Annual · latest fiscal year ends 2022-12-31